Trump Asks Pharma Companies to Lower Prices
President Donald Trump sent letters to AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, Gilead, GSK, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Regeneron and Sanofi, posting several of them online, telling them they should, within 60 days, set prices for Medicaid at the same level as the cheapest price their drugs are sold in a developed country; contract that when new drugs are launched, Medicaid, Medicare and private insurers all get that global low price; and allow direct-to-consumer sales for high-volume drugs, as long as those sales are at the same price as to insurers.
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
The White House said its trade negotiators would support the drugmakers' negotiating for better prices from health systems abroad, as long as the prices in the U.S. go down.
He asked for binding commitments by Sept. 29.